ImageneBio, Inc. (IMA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the date of July 25, 2025. The registrant, formerly known as Ikena Oncology, Inc., completed a previously announced merger with Inmagene Biopharmaceuticals (Inmagene) on this date. Concurrently, the company changed its name to ImageneBio, Inc. The transaction involved a two-step merger structure where Inmagene became a wholly-owned subsidiary of the surviving entity.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on the corporate event of the merger completion and name change.
Material Changes
- Corporate Structure: Inmagene Biopharmaceuticals is now a wholly-owned subsidiary of ImageneBio, Inc.
- Corporate Identity: The legal name changed from "Ikena Oncology, Inc." to "ImageneBio, Inc."
- Transaction Completion: The merger agreement dated December 23, 2024, was executed as planned.
Outlook, Risks, and Management Commentary
Management issued a press release on July 25, 2025, announcing the completion of the Merger and related matters (attached as Exhibit 99.1). The filing notes that the information in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. No specific forward-looking guidance, risk factors, or contingencies are detailed within the text of this specific 8-K form.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for details on the merger consideration, share exchange ratios, and post-merger capitalization.
- Verify the updated ticker symbol and trading status on the Nasdaq Capital Market under the new name "ImageneBio, Inc."
- Confirm the integration timeline and strategic rationale outlined in the press release.
- Check subsequent filings for the combined entity's first consolidated financial statements.